29-Mar-2018

NDF Research Senior Analyst Stuart Roberts interviews Kazia Therapeutics CEO Dr James Garner as the GDC-0084 phase II trial launches in the US

Kazia Therapeutics (ASX: KZA, NASDAQ: KZIA) is developing its lead therapeutic program, GDC-0084, for the deadly brain cancer, glioblastoma multiforme (GBM).

04-Jul-2017

CommSec Executive Series interviews CEO Dr James Garner on benefits of new business model for patients

CommSec's Tom Piotrowski speaks with Novogen Ltd (NRT) CEO & Executive Director, Dr James Garner about the company’s key milestones over the past 12 months and the clinical trials for its brain cancer treatment drug.

01-May-2017

Dr James Garner, CEO, speaks to Canary Networks investment forum

Novogen (ASX: NRT), Chief Executive Officer & Executive Director Dr James Garner , gives an update on Novogen since coming on board in 2016.

30-Jan-2017

CommSec interview re our new name, Kazia Therapeutics and our clinical trial progress

CommSec's Tom Piotrowski speaks with Kazia Therapeutics (KZA) CEO & Managing Director, Dr James Garner about the company’s recent name change from Novogen and progress of its ovarian cancer and brain cancer drug trials.

31-Oct-2016

Sky News Interview – In-licensing of GDC-0084

Novogen Sky News Interview